EGFR and non-small cell lung carcinoma: Another option that has been tested in order to improve the outcomes of second-line treatment of advanced EGFR mutant NSCLC after EGFR TKI therapy is the four-drug combination of immunotherapy, antiangiogenic therapy, and platin-based chemotherapy.